NovaCardia pockets $48M in second round

San Diego-based NovaCardia--which is developing drugs for cardiovascular disease--has raised $48 million in its second round. Skyline Ventures and InterWest Partners led the round with previous investors Domain Associates, Forward Ventures, Montreux Equity Partners, and Versant Ventures taking part as well. "This financing underscores the excitement around KW-3902 as a promising treatment for patients with CHF," added Randall E. Woods, president and CEO of NovaCardia.

- see the release on the round

Suggested Articles

Passage Bio filed to raise $125 million in its IPO. Now, it has outraised that goal by $91 million with a $216 million Wall Street debut.

The ruling reflects the judge’s belief that the FDA’s interpretation of the law on clinical trial reporting “is unlawful and must be set aside.”

Trutino will apply a platform designed to yield safer, more effective cytokines to the discovery of three oncology drugs for Boehringer.